The ALIM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALIM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALIM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALIM Detailed Price Forecast - CNN Money||View ALIM Detailed Summary - Google Finance|
|View ALIM Detailed Summary - Yahoo! Finance||View ALIM Stock Research & Analysis - Zacks.com|
|View ALIM Trends & Analysis - Trade-Ideas||View ALIM Major Holders - Barrons|
|View ALIM Call Transcripts - NASDAQ||View ALIM Breaking News & Analysis - Seeking Alpha|
|View ALIM Annual Report - CompanySpotlight.com||View ALIM OTC Short Report - OTCShortReport.com|
|View ALIM Fundamentals - TradeKing||View ALIM SEC Filings - Bar Chart|
|View Historical Prices for ALIM - The WSJ||View Performance/Total Return for ALIM - Morningstar|
|View the Analyst Estimates for ALIM - MarketWatch||View the Earnings History for ALIM - CNBC|
|View the ALIM Earnings - StockMarketWatch||View ALIM Buy or Sell Recommendations - MacroAxis|
|View the ALIM Bullish Patterns - American Bulls||View ALIM Short Pain Metrics - ShortPainBot.com|
|View ALIM Stock Mentions - StockTwits||View ALIM Stock Mentions - PennyStockTweets|
|View ALIM Stock Mentions - Twitter||View ALIM Investment Forum News - Investor Hub|
|View ALIM Stock Mentions - Yahoo! Message Board||View ALIM Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALIM - SECform4.com||View Insider Transactions for ALIM - Insider Cow|
|View ALIM Major Holdings Summary - CNBC||View Insider Disclosure for ALIM - OTC Markets|
|View Insider Transactions for ALIM - Yahoo! Finance||View Institutional Holdings for ALIM - NASDAQ|
|View ALIM Stock Insight & Charts - FinViz.com||View ALIM Investment Charts - StockCharts.com|
|View ALIM Stock Overview & Charts - BarChart||View ALIM User Generated Charts - Trading View|
Alimera Sciences Affirms Record 2018 Revenues
Posted on Monday January 07, 2019
ATLANTA, GA / ACCESSWIRE / January 7, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today affirmed that it expects record annual 2018 and fourth quarter 2018 revenues, with 2018 GAAP net revenue in excess of $45 million and fourth quarter 2018 GAAP net revenue in excess of $13 million. Additionally, Alimera anticipates reporting positive adjusted EBITDA for the three months ended December 31, 2018. In making this announcement, Alimera confirmed the previous estimates in its Current Report on Form 8-K dated December 4, 2018.
What Type Of Shareholder Owns Alimera Sciences, Inc.’s (NASDAQ:ALIM)?
Posted on Friday December 21, 2018
A look at the shareholders of Alimera Sciences, Inc. (NASDAQ:ALIM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...
Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.
Posted on Monday December 17, 2018
ATLANTA, GA / ACCESSWIRE / December 17, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that pricing approval had been received for ILUVIEN from the United Arab Emirates Ministry of Health & Prevention, effective January 24, 2019 through its partner MEAgate International FZLLC, headquartered in Dubai. "Diabetes is an important disorder in our region with a high prevalence and lower levels of control by patients of their disease," said Dr. Ahmed ElBarky, Assistant Professor of Opthalmology, Benha University, Egypt, consultant vitreoretinal surgeon, Sheikh Khalifa Medical Center in Abu Dhabi. "We are glad that ILUVIEN, which represents the latest medical introduction and innovation in the treatment of DME, is now available for our patients.
Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
Posted on Thursday November 29, 2018
ATLANTA, GA / ACCESSWIRE / November 29, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the company's Board of Directors has appointed Rick Eiswirth as Chief Executive Officer, effective January 2, 2019. Mr. Eiswirth will assume day-to-day leadership of the company, retain his title of President, and join Alimera's Board of Directors.